Market revenue in 2023 | USD 210.4 million |
Market revenue in 2030 | USD 781.8 million |
Growth rate | 20.6% (CAGR from 2023 to 2030) |
Largest segment | Adeno-associated virus (aav) |
Fastest growing segment | Adeno-associated virus (AAV) |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Adeno-associated virus (AAV), Lentivirus, Adenovirus, Retrovirus, Plasmids |
Key market players worldwide | Merck KGaA, Lonza Group Ltd, FUJIFILM Holdings Corp, Thermo Fisher Scientific Inc, Catalent Inc, WuXi Biologics (Cayman) Inc, Takara Bio Inc, Batavia Biosciences, Miltenyi Biotec, Revvity Inc, BioNTech SE ADR, Astellas Pharma Inc, Biomarin Pharmaceutical Inc, Regenxbio Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to viral vector and plasmid dna manufacturing market will help companies and investors design strategic landscapes.
Adeno-associated virus (aav) was the largest segment with a revenue share of 19.96% in 2023. Horizon Databook has segmented the Japan viral vector and plasmid dna manufacturing market based on adeno-associated virus (aav), lentivirus, adenovirus, retrovirus, plasmids covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is anticipated to account for a significant share of the Asia Pacific viral vectors and plasmid DNA manufacturing market, as it has one of the most developed pharmaceutical and biotechnology sectors in the region.
Moreover, the high prevalence of chronic diseases and rare genetic disorders has led to increase in R&D activities for the development of novel therapies and vaccines, creating high demand for DNA manufacturing solutions for research purposes.
For instance, in May 2020, Takara Bio contracted AGC Biologics to produce an intermediate COVID-19 DNA vaccine (a circular DNA [pDNA] that includes the target pathogen's protein).
Horizon Databook provides a detailed overview of country-level data and insights on the Japan viral vector and plasmid dna manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into Japan viral vector and plasmid dna manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account